What was IntelliPharmaCeutics International’s price range in the past 12 months?
IntelliPharmaCeutics International lowest stock price was $0.15 and its highest was $0.15 in the past 12 months.
What is IntelliPharmaCeutics International’s market cap?
IntelliPharmaCeutics International’s market cap is $2.38M.
When is IntelliPharmaCeutics International’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were IntelliPharmaCeutics International’s earnings last quarter?
IntelliPharmaCeutics International released its earnings results on Oct 16, 2023. The company reported -$0.054 earnings per share for the quarter.
Is IntelliPharmaCeutics International overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does IntelliPharmaCeutics International pay dividends?
IntelliPharmaCeutics International does not currently pay dividends.
What is IntelliPharmaCeutics International’s EPS estimate?
IntelliPharmaCeutics International’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IntelliPharmaCeutics International have?
IntelliPharmaCeutics International has 35,002,666 shares outstanding.
What happened to IntelliPharmaCeutics International’s price movement after its last earnings report?
IntelliPharmaCeutics International reported an EPS of -$0.054 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IntelliPharmaCeutics International?
Currently, no hedge funds are holding shares in IPCIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IntelliPharmaCeutics International
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of existing and new pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The company was founded by Isa Odidi and Amina Odidi in 1998 and is headquartered in Toronto, Canada.
Sector
Healthcare
Industry
Biotechnology
CEO
Isa Odidi
Employees
11
Website
www.intellipharmaceutics.com
Address
30 Worcester Road, Toronto, ON, M9W 5X2, CA
IntelliPharmaCeutics International (IPCIQ) Earnings & Revenues